tbuckley/cabot-search huggingface dataset:
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Authors: Rico D. Bense, Christos Sotiriou, Martine J. Piccart-Gebhart, John B. A. G. Haanen, Marcel A. T. M. van Vugt, Elisabeth G. E. de Vries, Carolien P. Schröder, Rudolf S. N. Fehrmann
Journal: JNCI Journal of the National Cancer Institute (2016)

Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy, resulting in considerable undertreatment or overtreatment. New insights into the role of tumor-infiltrating immune cells suggest that their composition, as well as their functionality, might serve as a biomarker to enable optimal patient selection for current systemic therapies and upcoming treatment options such as immunotherapy.We performed several complementary unbiased in silico analyses on gene expression profiles of 7270 unrelated tumor samples of nonmetastatic breast cancer patients with known clinical follow-up. CIBERSORT was used to estimate the fraction of 22 immune cell types to study their relations with pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). In addition, we used four previously reported immune gene signatures and a CD8+ T-cell exhaustion signature to assess their relationships with breast cancer outcome. Multivariable binary logistic regression and multivariable Cox regression were used to assess the association of immune cell-type fractions and immune signatures with pCR and DFS/OS, respectively.Increased fraction of regulatory T-cells in human epidermal growth factor receptor 2 (HER2)-positive tumors was associated with a lower pCR rate (odds ratio [OR] = 0.15, 95% confidence interval [CI] = 0.03 to 0.69), as well as shorter DFS (hazard ratio [HR] = 3.13, 95% CI = 1.23 to 7.98) and OS (HR = 7.69, 95% CI = 3.43 to 17.23). A higher fraction of M0 macrophages in estrogen receptor (ER)-positive tumors was associated with worse DFS (HR = 1.66, 95% CI = 1.18 to 2.33) and, in ER-positive/HER2-negative tumors, with worse OS (HR = 1.71, 95% CI = 1.12 to 2.61). Increased fractions of γδ T-cells in all breast cancer patients related to a higher pCR rate (OR = 1.55, 95% CI = 1.01 to 2.38), prolonged DFS (HR = 0.68, 95% CI = 0.48 to 0.98), and, in HER2-positive tumors, with prolonged OS (HR = 0.27, 95% CI = 0.10 to 0.73). A higher fraction of activated mast cells was associated with worse DFS (HR = 5.85, 95% CI = 2.20 to 15.54) and OS (HR = 5.33, 95% CI = 2.04 to 13.91) in HER2-positive tumors. The composition of relevant immune cell types frequently differed per breast cancer subtype. Furthermore, a high CD8+ T-cell exhaustion signature score was associated with shortened DFS in patients with ER-positive tumors regardless of HER2 status (HR = 1.80, 95% CI = 1.07 to 3.04).The main hypothesis generated in our unbiased in silico approach is that a multitude of immune cells are related to treatment response and outcome in breast cancer.
Regulation of NKT Cell Development by Sap, the Adaptor Mutated in X-Linked Lymphoproliferative Disease.
Authors: Kim E. Nichols, Jamie Hom, Arupa Ganguly, Cindie S. Ma, Stuart G. Tangye, Jennifer L. Cannons, Pamela L. Schwartzberg, Gary A. Koretzky, Paul L. Stein
Journal: Blood (2004)
Sentinel Lymph Node Biopsy in Cutaneous Melanoma
Authors: Elisa Tardelli, Sara Mazzarri, Domenico Rubello, Marta Gennaro, Lorenzo Fantechi, Valerio Duce, Antonella Romanini, Sotirios Chondrogiannis, Duccio Volterrani, Patrick M. Colletti, Gianpiero Manca
Journal: Clinical Nuclear Medicine (2016)

Melanoma is an important public health problem, and its incidence is increasing worldwide. The disease status of regional lymph nodes is the most important prognostic factor in early-stage melanoma patients. Sentinel lymph node biopsy (SLNB) was introduced in the early 1990s as a less invasive procedure than complete lymph node dissection to allow histopathologic evaluation of the "sentinel lymph node" (SLN), which is the first node along the lymphatic pathway from a primary tumor. Sentinel lymph node biopsy has minimal complication risks compared with standard complete lymph node dissection. Currently, SLNB is the accepted method for staging patients with clinically node-negative cutaneous melanoma and provides the most powerful prognostic information by evaluating the nodal basin status. The current practice of SLNB consists of the injection of Tc-labeled radiopharmaceutical, preoperative lymphoscintigraphy with the possibility of using the SPECT/CT hybrid imaging, and intraoperative SLN localization using a handheld gamma probe with or without the use of blue dye. Recently, the SLN localization and detection have been enhanced with the use of new tracers and new intraoperative devices, which have demonstrated to be particularly useful in melanomas of the head and neck region and in area of complex anatomy. Despite these important advances in the technology and the increasing experience in SLN mapping, major research centers have reported a false-negative rate higher than 15%. This relatively high false-negative rate, greater than those reported in the initial validation studies, points out the importance for the nuclear medicine community to continuously improve their knowledge on the biological behavior of melanoma and to improve the technical aspects that may allow more precise staging. For the SLNB procedure to be accurate, it is of critical importance that all "true" SLNs are identified and removed for examination. The aim of this article is to provide general information about the SLNB procedure in clinical practice highlighting the importance of standardization and accuracy of SLN identification in the light of the most recent technical innovations.
TCT-559 Long-term Clinical and Angiographic Impact of Stent Fracture on Second Generation Drug-eluting Stent Implantation: Comparison between Xience Everolimus- and Nobori Biolimus-eluting Stents
Authors: Masanobu Ohya, Kazushige Kadota, Takeshi Tada, Seiji Habara, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazuaki Mitsudo
Journal: Journal of the American College of Cardiology (2015)
TCT-421 Radial Approach versus Femoral Approach with Vascular Closure Devices: Systematic Review and Meta-analysis
Authors: Stefano Rigattieri, Alessandro Sciahbasi, Alessandro Alonzo, James Nolan, Nicholas Cox, Piotr Chodór, Andrea Berni, Francesco R. Pugliese, Massimo Volpe, Christopher J. Cooper, Sunil Rao, Yves Louvard
Journal: Journal of the American College of Cardiology (2015)
Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors.
Authors: Manish A. Shah, Alexander Starodub, Zev A. Wainberg, Meihua Wu, Victoria Smith, Julia D. Maltzman, Johanna C. Bendell
Journal: Journal of Clinical Oncology (2016)

4033 Background: GS-5745 is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9), an extracellular enzyme involved in matrix remodeling, tumor growth, and metastasis. Preclinical studies demonstrate that MMP9 inhibition alters the tumor microenvironment, associated with greater chemotherapy penetration and improved anti-tumor immunity. Methods: We performed a phase I study of GS-5745 in combination with various chemotherapy regimens (Bendell, ASCO 2015). The expanded cohort of GC evaluated mFOLFOX with GS-5745 800 mg IV every 2 weeks. Serial blood samples were evaluated for correlative evidence of MMP-9 inhibition. Clinical Trial Information: NCT01803282. Results: As of January 12, 2016, 40 patients (pts) with metastatic GC were treated (14 remain on study). Grade 3 or higher treatment-emergent AEs (TEAEs) included neutropenia (18%), nausea (10%), and neutrophil count decreased (10%). The most common serious TEAEs were abdominal pain, GI hemorrhage, hyponatremia, nausea, pyrexia and septic shock each occurring in 2 pts (5%). Median progression free survival (PFS) for all 40 pts is 7.4 months (90% confidence interval (CI) = [5, 12]), with a median duration of response (DOR) of 9.4 months and an objective response rate (ORR) of 50%. Of those pts, 30 pts were chemotherapy naïve (eg. 1stline), and demonstrated a median PFS of 12 (90% CI = [5.5, 18]) months, with a median DOR of 11 months and an ORR of 57%. Collagen neoepitope decreased with continued treatment, demonstrating on-target effects. Conclusions: Adding GS-5745 to mFOLFOX is feasible and well tolerated, and associated with encouraging activity. Biomarker studies demonstrate MMP-9 inhibition. For treatment naïve pts, the median PFS was considerably longer than expected (12 months). GS-5745 is now being examined in a registrational phase III study in 1st line GC with mFOLFOX chemotherapy. Clinical trial information: NCT01803282.
TCT-6 Five-year optical coherence tomography of patients with ST-elevation myocardial infarction treated with bare-metal versus everolimus-eluting stents: the RE-EXAMINATION study
Authors: Josep Gomez Lara, Salvatore Brugaletta, Francisco Jacobi, Luis Ortega-Paz, Marcos Nato, Gerard Roura, Joan A. Gomez Hospital, Manel Sabate, Angel Cequier
Journal: Journal of the American College of Cardiology (2015)
Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma
Authors: Susana Puig, Francesca Sampogna, Antonio Tejera-Vaquerizo
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
TCT-194 Current Indications And Outcomes Of Intra-Aortic Balloon Pump (IABP) Counterpulsation And Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO): The Liverpool Hospital Experience
Authors: James Xu, Andrew Hopkins, Dominic Y. Leung, Christian J. Mussap, Rohan Rajaratnam, John K. French, Craig P. Juergens, Sidney Lo
Journal: Journal of the American College of Cardiology (2015)
Unmet Needs for Ancillary Services Among Hispanics/Latinos Receiving HIV Medical Care — United States, 2013–2014
Authors: Lauren C. Korhonen, Nicholas P. DeGroote, R. Luke Shouse, Linda A. Valleroy, Joseph Prejean, Heather Bradley
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The prevalence of diagnosed human immunodeficiency virus (HIV) infection in Hispanics/Latinos in the United States is more than twice as high as the prevalence among non-Hispanic whites (1). Services that support retention in HIV medical care and assist with day-to-day living, referred to here as ancillary services, help persons living with HIV access HIV medical care, adhere to HIV treatment, and attain HIV viral suppression. The needs for these ancillary services among Hispanics/Latinos are not well described (2). To obtain nationally representative estimates of and reasons for unmet needs for such services among Hispanic/Latino adults receiving outpatient HIV medical care during 2013-2014, CDC analyzed data from the Medical Monitoring Project (MMP). The analysis found that Hispanics/Latinos in all age and sexual orientation/behavior subgroups reported substantial unmet needs, including 24% needing dental care, 21% needing eye or vision care, 15% needing food and nutrition services, and 9% needing transportation assistance. Addressing unmet needs for ancillary services among Hispanics/Latinos living with HIV might help increase access to HIV care, improve health outcomes, and reduce health disparities.
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia
Authors: Phuong-Hien Nguyen, Oleg Fedorchenko, Natascha Rosen, Maximilian Koch, Romy Barthel, Tomasz Winarski, Alexandra Florin, F. Thomas Wunderlich, Nina Reinart, Michael Hallek
Journal: Cancer Cell (2016)
Secondary Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients
Authors: Qifa Liu, Ren Lin, Jing Sun, Yu Zhang, Fen Huang, Zhiping Fan, Hongsheng Zhou, Qianli Jiang, Fuhua Zhang, Xiao Zhai, Dan Xu, Yongqiang Wei
Journal: Blood (2012)
Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML
Authors: Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske, Jan Braess, Achim Heinecke, Maria C. Sauerland, Wolfgang E. Berdel, Thomas Buechner, Wolfgang Hiddemann, Karsten Spiekermann
Journal: Blood (2008)
TCT-222 Long-Term Use of Dual antiplatelets For The Secondary Prevention of Atherothrombotic Events In Patients with Coronary Artery Disease: Meta-analysis of Randomized Controlled Trials.
Authors: Zaher Fanari, Amratash Malodiya, Sandra Weiss, Sumaya Hammami, Paul Kolm, William Weintraub
Journal: Journal of the American College of Cardiology (2015)
TCT-695 The Incidence of Paravalvular Leak in Transthoracic Echocardiography-guided deployment of Transcatheter Aortic Valve is Comparable to that of Transesophageal Echocardiography-guided Deployment: An Update of the Emory Experience
Authors: Salim S. Hayek, Jose F. Condado, Nikolaos Spilias, Shuang Lin, James P. Macnamara, Shuai Zheng, Patricia Keegan, Vasilis Babaliaros, Vinod Thourani, Stamatios Lerakis
Journal: Journal of the American College of Cardiology (2015)
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
Authors: Marzia Del Re, Elisa Biasco, Stefania Crucitta, Lisa Derosa, Eleonora Rofi, Cinzia Orlandini, Mario Miccoli, Luca Galli, Alfredo Falcone, Guido W. Jenster, Ron H. van Schaik, Romano Danesi
Journal: European Urology (2016)
TCT-321 Peripheral MicroRNAs May Serve As Novel Biomarkers For Identification Of Coronary Artery Calcification
Authors: Philippa J. Howlett, Alex Horton, Edward W. Leatham, Abdul Waheed, Huihai Wu, Nikunj R. Shah, Andre Gerber, Michael Mahmoudi
Journal: Journal of the American College of Cardiology (2015)
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Authors: Lee S. Rosen, Jonathan W. Goldman, Alain P. Algazi, P. Kellie Turner, Brian Moser, Tianle Hu, Xuejing Aimee Wang, Jay Tuttle, Volker Wacheck, James E. Wooldridge, Michaela Banck
Journal: Clinical Cancer Research (2016)

Abstract Purpose: The MET/HGF pathway regulates cell proliferation and survival and is dysregulated in multiple tumors. Emibetuzumab (LY2875358) is a bivalent antibody that inhibits HGF-dependent and HGF-independent MET signaling. Here, we report dose escalation results from the first-in-human phase I trial of emibetuzumab. Experimental Design: The study comprised a 3+3 dose escalation for emibetuzumab monotherapy (Part A) and in combination with erlotinib (Part A2). Emibetuzumab was administered i.v. every 2 weeks (Q2W) using a flat dosing scheme. The primary objective was to determine a recommended phase II dose (RPTD) range; secondary endpoints included tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity. Results: Twenty-three patients with solid tumors received emibetuzumab monotherapy at 20, 70, 210, 700, 1,400, and 2,000 mg and 14 non–small cell lung cancer (NSCLC) patients at 700, 1,400, and 2,000 mg in combination with erlotinib 150 mg daily. No dose-limiting toxicities and related serious or ≥ grade 3 adverse events were observed. The most common emibetuzumab-related adverse events included mild diarrhea, nausea, and vomiting, and mild to moderate fatigue, anorexia, and hypocalcemia in combination with erlotinib. Emibetuzumab showed linear PK at doses &amp;gt;210 mg. Three durable partial responses were observed, one for emibetuzumab (700 mg) and two for emibetuzumab + erlotinib (700 mg and 2,000 mg). Both of the responders to emibetuzumab + erlotinib had progressed to prior erlotinib and were positive for MET protein tumor expression. Conclusions: Based on tolerability, PK/PD analysis, and preliminary clinical activity, the RPTD range for emibetuzumab single agent and in combination with erlotinib is 700 to 2,000 mg i.v. Q2W. Clin Cancer Res; 23(8); 1910–9. ©2016 AACR.
Pulmonary metastasectomy in cases with primary tumor under control
Authors: C. Parlak, R. Demirhan, A. Mayadagli, M. Kocak
Journal: Journal of Clinical Oncology (2008)

21511 Background: It is known that metastasectomy performed to patients whose primary tumors are under control improves the survival. Aim of this study is to investigate the efficacy and survival benefit of pulmonary metastasectomy. Methods: Fifty patients who had been followed up in our clinic with the primary tumor under control, and who underwent metastasectomy of solitary pulmonary metastases were evaluated retrospectively. Results: A total of 50 cases were included in the study, 31 (62%) of which were male. Mean age was 32.5 (16–52). Lateral limited toracotomy was performed to 42 cases (84%), and stepwise toracotomy was carried out in 8 cases. Resection was complete in al patients. Median number of metastasis was 4.1 (1–12). There were bilateral metastases in 8 cases, and toracotomy was performed 3-times in one patient. Surgical operations were wedge resection in 36 cases (72%), nodulectomy in 10 cases (20%) and lobectomy in 4 cases (8%). Most common postoperative histopathologic type was osteosarcoma. Mean hospitalization time was 5.4 days. There was no mortality event in our series, and the only morbidity was extended air-leakage experienced in one case. Fifty-five percent of patients are still alive with no problem. Conclusions: As pulmonary metastasectomy has considerable impact on improved survival in secondary tumors of lung, as mortality and morbidity rates are low, and as hospital-stay period is short, we believe that it can be a treatment of choice in patients with the primary lesion under control and in those who are eligibile for complete resection. No significant financial relationships to disclose.
Prognostic Impact of Posttransplantation Serum Ferritin In Allogeneic Stem Cell Transplantation for Leukemia or Myelodysplastic Syndrome.
Authors: Heiwa Kanamori, Takayoshi Tachibana, Ayumi Numata, Masatsugu Tanaka, Yoshiaki Ishigatsubo, Atsuo Maruta
Journal: Blood (2010)
Pheochromocytoma: The First Metabolic Endocrine Cancer
Authors: Ivana Jochmanova, Karel Pacak
Journal: Clinical Cancer Research (2016)

Dysregulated metabolism is one of the key characteristics of cancer cells. The most prominent alterations are present during regulation of cell respiration, which leads to a switch from oxidative phosphorylation to aerobic glycolysis. This metabolic shift results in activation of numerous signaling and metabolic pathways supporting cell proliferation and survival. Recent progress in genetics and metabolomics has allowed us to take a closer look at the metabolic changes present in pheochromocytomas (PHEO) and paragangliomas (PGL). These neuroendocrine tumors often exhibit dysregulation of mitochondrial metabolism, which is driven by mutations in genes encoding Krebs cycle enzymes or by activation of hypoxia signaling. Present metabolic changes are involved in processes associated with tumorigenesis, invasiveness, metastasis, and resistance to various cancer therapies. In this review, we discuss the metabolic nature of PHEOs/PGLs and how unveiling the metabolic disturbances present in tumors could lead to identification of new biomarkers and personalized cancer therapies. Clin Cancer Res; 22(20); 5001-11. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "ENDOCRINE CANCERS REVISING PARADIGMS".
Detection of the Acquired Tyrosine Kinase JAK2 Gene Mutation by Real Time PCR as Minimal Residual Disease Marker for Patients after Allogeneic Hematopoetic Stem Cell Transplantation.
Authors: Ahmet H. Elmaagacli, Nina K. Steckel, Michael Koldehoff, Markus Ditschkowski, Rudolf Trenschel, Dietrich W. Beelen
Journal: Blood (2005)
M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation
Authors: Prashanth K. Kandalla, Sandrine Sarrazin, Kaaweh Molawi, Carole Berruyer, David Redelberger, Anne Favel, Christophe Bordi, Sophie de Bentzmann, Michael H. Sieweke
Journal: The Journal of Experimental Medicine (2016)

Myeloablative treatment preceding hematopoietic stem cell (HSC) and progenitor cell (HS/PC) transplantation results in severe myeloid cytopenia and susceptibility to infections in the lag period before hematopoietic recovery. We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instructed myeloid commitment in HSCs. In this study, we tested whether this effect had therapeutic benefit in improving protection against pathogens after HS/PC transplantation. M-CSF treatment resulted in an increased production of mature myeloid donor cells and an increased survival of recipient mice infected with lethal doses of clinically relevant opportunistic pathogens, namely the bacteria Pseudomonas aeruginosa and the fungus Aspergillus fumigatus M-CSF treatment during engraftment or after infection efficiently protected from these pathogens as early as 3 days after transplantation and was effective as a single dose. It was more efficient than granulocyte CSF (G-CSF), a common treatment of severe neutropenia, which showed no protective effect under the tested conditions. M-CSF treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-CSF, did not impede recovery of HS/PCs, thrombocyte numbers, or glucose metabolism. These results encourage potential clinical applications of M-CSF to prevent severe infections after HS/PC transplantation.
GW27-e0547 Real World Treatment and its Long Term Clinical Outcomes Between DES and CABG in Patients With Left Main Disease, Single Center Experience
Authors: Seung Hwan Han, Pyung Chun Oh, Min Soo Kim, Woong Chol Kang, Sun Yong Suh, Kyounghoon Lee, Tae Hoon Ahn, Eak Kyun Shin
Journal: Journal of the American College of Cardiology (2016)
CXCR4 Is a Regulator Of Disease Involvement Of Extramedullary Myeloma Confirmed By a Novel Mouse Model For Extramedullary Disease
Authors: Yuji Mishima, Michele Moschetta, Michaela R Reagan, Yong Zhang, Ilyas Sahin, Niraj Maulkhan, Aldo M Roccaro, Irene M. Ghobrial
Journal: Blood (2013)